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The Medicare Part D medication therapy management (MTM) program positions pharmacists to 
optimize beneficiaries’ medications and improve care. Little is known regarding Part D MTM delivery by 
community pharmacists and other pharmacist provider types.  
 
Objectives: 
To (1) characterize Medicare Part D MTM delivery by community pharmacists, (2) compare MTM 




A descriptive cross-sectional study using merged data from a 20% random sample of Medicare 
beneficiary enrollment data with a 100% sample of recently available 2014 Part D MTM files was 
conducted. Andersen’s Behavioral Model was applied to describe MTM delivery across beneficiary 
characteristics. Descriptive and bivariate statistics were used to compare delivery of MTM between 
community and other pharmacist providers.  
 
Results:  
Among beneficiaries sampled, community pharmacists provided comprehensive medication reviews 
(CMRs) to 22% (n=26,337) of beneficiaries receiving at least one CMR. Almost half (49.4%) were 
provided face-to-face. Across pharmacist cohorts, median days to CMR offer of post-MTM program 
enrollment were within the 60-day policy requirement. The community pharmacist cohort had fewer 
days from CMR offer to receipt (median 47 days). Community pharmacists provided more medication 
therapy problem (MTP) recommendations (mean [SD] of 1.8 [3.5]; p<0.001), but resolved less MTPs (0.2 
[0.7]; p<0.001), and most commonly served beneficiaries that were in the south but less in the 
west/northeast. Additionally, community pharmacists served a smaller proportion of black beneficiaries, 
yet a larger proportion of Hispanic beneficiaries (p<0.001).  
 
Conclusion: 
Community pharmacists provided approximately one in five CMRs for MTM eligible beneficiaries in 
2014, with CMRs occurring more quickly, resulting in more MTP recommendations, but resolving less 
MTPs than those provided by non-community pharmacists. Future research should explore 
geographic/racial-ethnic disparities in beneficiaries served and strategies to increase negligible MTP 




Community Pharmacists, Medication Therapy Management, Medicare Part D 
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Preventable medication therapy problems (MTPs) are a major public health concern in the United 
States, affecting over seven million patients and costing nearly $21 billion annually across inpatient and 
outpatient health care settings.1 Community pharmacists can serve as a resource to improve medication 
use. Pharmacists may provide medication management services, including “services that focus on 
medication appropriateness, effectiveness, safety, and adherence with the goal of improving health 
outcomes” as defined by the Joint Commission of Pharmacy Practitioners.2 Medication therapy 
management (MTM) is an example of a medication management service.2,3  
 
The complex medication needs of Medicare beneficiaries may be met by MTM, and is required as one 
component of Medicare Part D. In Part D MTM, eligible beneficiaries must be offered an annual 
comprehensive medication review (CMR) and quarterly targeted medication reviews (TMRs), with 
follow-up provided on any medication therapy problem (MTP) recommendations.4 Several models for 
MTM delivery have been reported, including contracts with MTM vendors who provide services either 
“in-house” or through contracts with “external” providers, such as community pharmacists.5 Although 
“any qualified provider” may provide MTM, plans have reported most commonly using pharmacists.5 
Heterogeneity among pharmacists providing MTM in the outpatient6 call-center and community 
pharmacy settings7 have been reported, including variations in MTM service characteristics, populations 
served, and MTM practice maturity level, making it difficult to measure outcomes.6,7  Therefore, it is 
unknown how MTM delivery models could be tailored to different population segments in order to 
optimize outcomes. Moreover, challenges unique to MTM delivery in the community pharmacy setting 
exist. For example, the need to redefine workflow to incorporate MTM has been noted as a barrier.8-10 
Defining and developing new roles for support staff have been emphasized.9,11-13 Moreover, community 
pharmacists have struggled with patient and prescriber understanding and acceptance of MTM 
services.8,14-16 Additional barriers reported include high demand for dispensing-related activities, 
cumbersome MTM documentation, insufficient staff training, and inadequate staffing hours.8,9,17-19  
 
Despite the barriers to providing MTM services in the community pharmacy setting, community 
pharmacists also have unique advantages to delivering MTM, such as established relationships with 
patients through prescription fulfillment services. However, little information is available regarding the 
extent of community pharmacist involvement in Part D MTM, the characteristics of beneficiaries served 
by community pharmacists as opposed to other pharmacist providers, and the variation in MTM delivery 
by community pharmacists compared with other pharmacist providers. This information could provide a 
foundation for future research comparing MTM delivery models. Therefore, the objectives of this study 
were to (1) characterize Medicare Part D MTM delivery by community pharmacists, (2) compare MTM 
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This hypothesis-generating descriptive study used a cross-sectional design to compare MTM delivery 
between beneficiaries receiving CMRs from one of three different pharmacist provider type cohorts: 
community pharmacists, MTM vendor in-house pharmacists, and Medicare Part D plan pharmacists.   
 
Data Sources 
We used a number of administrative claims data files obtained from the Centers for Medicare & 
Medicaid Services (CMS) through a third party contractor called ResDAC; more detailed information is 
available online.20 These files were used to describe beneficiary characteristics and the delivery of MTM 
services. We obtained a 20% random sample of the 2014 Medicare master beneficiary summary file and 
Parts A, B, and D health claims data, as well as a 100% sample of the 2014 Part D MTM files. These files 
represent a recent expansion of data resources provided by CMS and were first made available for 
research in 2017. Beneficiary characteristics (e.g., age, gender, race, plan enrollment, and area of 
residence) are contained in the master beneficiary summary file. In addition, we also used Parts A, B, 
and D claims data to capture inpatient, outpatient, and prescription medication utilization under the 
Medicare program. The Part D MTM files contain detailed information regarding enrollment in the MTM 
program, dates of CMR offer, dates of CMR receipt, method of CMR delivery, and the type of CMR 
provider. In addition, a number of summary variables describing the delivery of MTM services are also 
provided for each beneficiary in the MTM file including annual counts of MTP recommendations, MTPs 
resolved, and TMRs received.  
Cohort Definitions 
For this paper, we limit our description of the delivery of MTM services to Medicare beneficiaries eligible 
for benefits due to age qualification (Figure). Beneficiaries were eligible for inclusion in this study if they 
were 65 and older and they were continuously enrolled in Medicare Parts A, B, and D for all 12 months 
of the 2014 calendar year. To describe MTM service delivery and the types of providers, we limited the 
population to beneficiaries in the 20% random sample that linked to the Part D MTM files receiving at 
least one CMR in 2014 by a (1) community, (2) plan, or (3) vendor in-house pharmacist. The community 
pharmacist cohort included beneficiaries with CMRs coded as delivered by “local pharmacists” and 
“MTM vendor local pharmacists” as these represent community pharmacists providing MTM through 
contracts directly between the plan and the community pharmacy or through an MTM vendor as an 
intermediary. The plan pharmacist cohort included beneficiaries with CMRs coded as provided by 
pharmacists employed directly by plans as well as pharmacists employed by a pharmacy benefit 
manager (PBM). These providers were combined as both the plan and PBM’s revenue focuses on 
medical/prescription claims rather than MTM. The MTM vendor in-house pharmacist cohort included 
beneficiaries with CMRs coded as delivered by “MTM vendor in-house pharmacists” which represents 
pharmacists employed directly (not “external” contracts) by MTM vendors. 
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Individuals aged 64 and younger and individuals eligible for Medicare through end-stage renal disease 
(ESRD) or other disabilities were excluded.  
Variables 
To describe beneficiary characteristics, we used the Andersen Behavioral Model of Health Services Use 
as a conceptual framework to group individual determinants of health care utilization variables into 
predisposing, enabling, and need characteristics.21,22 According to the model, an individual’s use of a 
health service (e.g., MTM) is dependent on their predisposing characteristics, ability to use the health 
service (enabling), and need for the service.21,22  
For the purposes of this study, predisposing characteristics included age as a continuous variable, 
gender, and race/ethnicity. Enabling variables included geographic region of the country (Northeast, 
South, Midwest, West, and Other Region) and urban residence.23 Additionally, an income assistance 
status variable for Medicare enrollment24 (Medicare/Medicaid dual enrollment, qualified Medicare 
beneficiary enrollment, specified low-income Medicare beneficiary enrollment, or no income assistance) 
was included.  Lastly, given the unique benefit design of Part D in which patient out-of-pocket 
copayment rates vary at different levels of prescription spend, we described MTM delivery across 
copayment status. Copayment status was hierarchically defined as the maximum stage of the Part D 
benefit achieved throughout the calendar year from (1) catastrophic coverage to (2) prescription use in 
the coverage gap (e.g., donut hole) to (3) no coverage gap exposure.  
Finally, need variables included any inpatient hospitalization or emergency department visits within the 
calendar year. To evaluate the burden of health conditions and medication use, we used the Elixhauser 
Index and a count of therapeutic drug classes prescribed to beneficiaries during the year.25 Beneficiaries 
were categorized as having a condition if there was at least one inpatient and/or two outpatient codes 
within the calendar year for each condition. We used a simple count of the 30 Elixhauser conditions to 
describe disease burden as well as weighted Elixhauser indices shown to be predictive of readmission to 
the hospital and overall mortality.26 
The MTM delivery variables evaluated included (1) beneficiary entry into MTM program, (2) beneficiary 
MTM services received, and (3) pharmacist provider interventions. First, entry into MTM program 
variables included days from plan enrollment to MTM enrollment, days from MTM enrollment to CMR 
offer, days from CMR offer to first CMR received, and Part D contract type (managed care, prescription 
drug plan [PDP], or employer sponsored). For Part D contract type, we collapsed managed care 
preferred provider organizations (PPOs) and regional PPOs into “managed care” as managed care 
programs generally have higher standards to meet for the CMS Star Ratings and thus are more 
incentivized to design robust MTM programs.27 Second, variables for MTM services received included 
CMR delivery method (face-to-face, telephone, telehealth), number of CMRs and TMRs received, and 
CMR recipient (beneficiary, beneficiary's prescriber, caregiver/other authorized individual). Per 2014 
CMS guidance,28 we grouped “other authorized individual” with “caregiver” for analytical purposes.  
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Lastly, pharmacist-prescriber intervention variables included number of MTP recommendations made 
and number of MTP resolutions.  
Statistical Analysis 
Descriptive statistics were computed using SAS v 9.4 software29 to describe MTM delivery in 2014 across 
the three pharmacist provider types. Bivariate statistics were used to assess differences in MTM delivery 
across pharmacist cohorts. We compared beneficiaries receiving a CMR from a community pharmacist 
to those receiving a CMR from a plan pharmacist and from a vendor in-house pharmacist in separate 
analyses. Chi-square tests were used to compare categorical variables and two-tailed t-tests or Wilcoxon 
rank-sum tests were used for continuous variables when appropriate. An alpha of 0.05 or lower was 
deemed significant for all statistical analyses.  
This study was approved by the University of Minnesota Institutional Review Board.  
Results 
Among the 20% random sample of continuously enrolled Medicare beneficiaries qualified for benefits 
through aged enrollment criteria, 119,181 beneficiaries received a CMR in 2014 (Figure). Community 
pharmacists provided 22% of these CMRs, 30% were provided by plan pharmacists, and 35% were 
provided by vendor in-house pharmacists (Table 1). Approximately 12% of CMRs were provided by other 
pharmacist and health care provider types. These data are reported to provide full context but were not 
included in subsequent analyses. 
Beneficiary predisposing, enabling, and need characteristics are compared across the three pharmacist 
cohorts: (1) community, (2) plan, and (3) vendor in-house pharmacist in Table 2. 
Predisposing Characteristics  
Across all three pharmacist cohorts, beneficiaries were approximately 75 years of age and 37-38% were 
male. Community pharmacists served a smaller proportion of black beneficiaries (11.4%; p<0.001) 
compared with plan and vendor in-house pharmacist providers (13.2% and 12.5%, respectively). 
However, community pharmacists served a larger proportion of Hispanic beneficiaries (14.2%; p<0.001); 
almost double the proportion of beneficiaries served by vendor in-house pharmacists (7.6%).  
Enabling Characteristics 
The majority of beneficiaries receiving CMRs were urban residents across the three pharmacist provider 
cohorts; however, community pharmacists served more rural-residing beneficiaries (18.6%; p<0.001) 
compared with plan pharmacists (11.4%). A larger proportion of beneficiaries served by community 
pharmacists resided in the south (57.6%; p<0.001) compared with plan (32.5%) and vendor in-house 
pharmacist providers (34.5%). However, community pharmacists served smaller proportions of 
beneficiaries residing in the northeast and west (8.4% and 9.6%, respectively) compared with vendor in-
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house pharmacists (25.5% and 16.1%) and plan pharmacists (13.7% and 34.5%) respectively.  Across all 
three pharmacist cohorts, the majority of beneficiaries  lacked a low income assistance enrollment 
subsidy, however, those without a subsidy were less served by community pharmacists than by plan 
pharmacists (72.4% and 81.3%, respectively; p<0.001).  
Need Characteristics 
Community pharmacists provided CMRs to more cognitively impaired beneficiaries (4%) compared with 
both plan (3%) and vendor in-house (1%) pharmacists (p<0.001). When comparing other need variables 
(e.g., emergency department visit, Elixhauser conditions, hospitalization), the community pharmacist 
cohort comprised a slightly “sicker” (i.e., “needier”) population than the plan pharmacist cohort, but a 
healthier population than the MTM vendor in-house pharmacist cohort. 
Table 3 compares MTM delivery by pharmacist provider type including (1) beneficiary entry into MTM 
program, (2) MTM services received, and (3) MTM interventions made. 
Beneficiary Entry into MTM Program 
Beneficiaries receiving MTM services from community pharmacists were enrolled into the MTM 
program within a median (25th percentile, 75th percentile) of 31 days (0, 100) from plan enrollment, 
which was significantly fewer days than beneficiaries receiving MTM services from plan or vendor in-
house pharmacists (48 [0, 111] and 33 days [26, 119], respectively; p<0.001). The number of days 
between MTM enrollment and the CMR offer differed by pharmacist type, with the CMR offer occurring 
at a median (25th percentile, 75th percentile) of 28 (9, 38) days for community pharmacists, 9 (0, 26) days 
for plan pharmacists, and 16 (4, 28) for vendor in-house pharmacists (p<0.001). More beneficiaries in 
the community pharmacist cohort received the CMR offer greater than 60 days post-MTM program 
enrollment compared with plan and vendor in-house pharmacists. However, beneficiaries within the 
community pharmacist cohort had fewer median (25th percentile, 75th percentile) days between CMR 
offer to CMR receipt (47 [20, 140]; p<0.001), compared with plan (76 [32, 155]) and vendor in-house (94 
[31, 194]) pharmacist cohorts. Among beneficiaries receiving CMRs from community pharmacists 
compared with plan pharmacists, there were no differences in beneficiary contract type (i.e., managed 
care vs. PDP). However, the payer mix for beneficiaries receiving CMRs from community pharmacists 
was significantly different from those receiving CMRs from MTM vendor in-house pharmacists 
(p<0.001). 
MTM Services Received  
Community pharmacists provided more CMRs face-to-face (49%; p<0.001) compared with plan and 
vendor in-house pharmacists (1% and 0%, respectively). For all three pharmacist provider types, at least 
85% of CMRs provided were to the beneficiary. The community pharmacist cohort provided more TMRs 
than the plan pharmacist cohort (mean [SD] of 10.29 [8.9] vs. 5.71 [6.7], respectively; p<0.001), but less 
than the MTM vendor in-house pharmacist cohort (mean [SD] of 10.29 [8.9] vs. 18.36 [18], p<0.001). 
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MTM Interventions Made 
Community pharmacists made slightly more MTP recommendations to prescribers (mean [SD] of 1.8 
[3.5]; p<0.001) compared with plan and vendor in-house pharmacists (1.17 [2.5] and 1.64 [2.8], 
respectively). However, community pharmacists resolved slightly fewer MTPs (0.22 [0.7]; p<0.001) 
compared with plan and vendor in-house pharmacists (0.33 [0.9] and 0.35 [0.8], respectively). 
Discussion 
 
This is the first study, to our knowledge, to use a nationally representative sample of MTM beneficiaries 
to examine MTM delivery by community pharmacists. We found that of Medicare beneficiaries receiving 
at least one CMR in 2014, approximately 20% had the CMR provided by a community pharmacist. This 
finding appears to align with previous estimates from CMS that the use of MTM vendor-contracted 
community pharmacists occurred with only 26% of plans in 2014.30 However, utilization of community 
pharmacists for Part D MTM has grown, with about 65% of plans reporting use of MTM vendor-
contracted community pharmacists in 2018.5 Therefore, better understanding of MTM delivery by 
community pharmacists has important practice implications. 
 
We observed some differences between beneficiaries served by community pharmacists versus plan or 
MTM vendor in-house pharmacists. It is important to note that given the large sample sizes in this study, 
comparisons between cohorts were all statistically significant. However, statistical significance does not 
always imply clinical or policy significance. For this reason, we focus the discussion of results on findings 
with more meaningful clinical and/or policy implications. For example, we noted regional and 
racial/ethnic variation in beneficiaries served by community pharmacists compared with the other 
pharmacist provider cohorts. In addition, smaller proportions of patients lacking a low-income subsidy 
status24 were served by community pharmacists, indicating a less wealthy beneficiary cohort. Generally, 
beneficiaries served by community pharmacists appeared to be less medically complex than those 
served by MTM vendor in-house pharmacists, but more complex than those served by plan pharmacists. 
However, community pharmacists served a greater proportion of patients with cognitive impairment. 
Reasons for these differences are unknown and pose clinical/policy implications and thus, future 
research is warranted.  
 
CMS guidance requires that plans offer beneficiaries newly eligible for MTM a CMR within 60 days of 
enrollment into the MTM program.4,28 Across all pharmacist provider cohorts examined, most CMRs 
were compliant with this requirement (medians of 28, 9, and 16 days for community, plan, and vendor 
in-house pharmacists, respectively). However, community pharmacists provided the greatest proportion 
of CMR offers greater than 60 days post-enrollment (6%). Reasons for this are unclear; it is conceivable 
that these beneficiaries were uniquely transient and unable to be reached at earlier time points. It is 
also unclear whether a plan representative was responsible for making offers prior to contact by the 
community pharmacist and the method (e.g., letter, phone outreach) by which offers were made.  
 
This article is protected by copyright. All rights reserved.
Interestingly, the time from offer to CMR completion was the shortest for patients served by community 
pharmacists (medians of 47, 76, and 94 days for community, plan, and vendor in-house pharmacists 
respectively; p<0.001). Currently, CMS does not provide guidance on when a CMR must occur following 
an offer. Rather, with the inclusion of CMR completion rates as a Star Measure, plans are incentivized to 
ensure CMR completion occurs at some point during the calendar year.31 It is possible that, given 
declines in drug product reimbursements (e.g., direct and indirect remuneration fees32) since 2010,33 
community pharmacists could feel increased pressure as compared with plan and MTM vendor in-house 
pharmacists to prioritize the completion of CMRs. Additionally, it is possible that personal relationships 
between community pharmacists and their patients resulted in more rapid patient acceptance of CMR 
offers. Recent literature has evaluated strategies, such as the use of scripted language, as well as phone 
calls and bag stuffers, for encouraging patients to accept CMR offers.15,34-36 As these practices become 
more common, research should examine whether changes in time from offer to CMR completion occur 
across provider types or are unique to specific provider types. 
 
Not surprisingly, community pharmacists were the only pharmacist provider cohort examined that 
provided a meaningful number of CMRs face-to-face with patients and/or caregivers. However, it is 
notable that about half of community pharmacist-provided CMRs were conducted by telephone. Since 
2014, telephonic MTM delivery by community pharmacists has become even more common, and MTM 
provision over video-conferencing has emerged.37  Future research should explore the effects of MTM 
delivery mode on patient outcomes, and whether variation is found by provider type.  
 
We found that community pharmacists, as compared with plan and MTM vendor in-house pharmacists, 
made slightly more MTP recommendations to prescribers. However, on average, slightly fewer MTP 
resolutions occurred. Additionally, the majority of beneficiaries served by community pharmacists were 
urban residents; however, community pharmacists served more rural residents compared with plan 
pharmacists. These findings align with existing literature that has identified prescriber relationships and 
temporal/spatial location as a barrier for MTM delivery and MTP resolution.16,38 The inclusion of 
pharmacists in health information exchange is an important first step and the need for such has been 
noted previously. One study showed that having access to and sending medication recommendations 
using the electronic health record that physicians use resulted in efficient communications and timely 
medication changes.39  Therefore, without prescriber buy-in, information exchange will likely be 
insufficient for MTP resolution. Prior research found that while community pharmacists identified more 
MTPs during a CMR when having access to patient health records, they reported no difference in their 
confidence to resolve MTPs.40 Another study showed that trust is often the basis for pharmacist-
physician collaborative relationships and recommendation acceptance.41 Medicare Part D MTM models 
in which community pharmacists practice under collaborative drug therapy management should be 
explored to determine whether MTP resolution is improved.  
 
This study has limitations. Analyses were conducted for a 20% random sample of Medicare beneficiaries 
nationwide, linked to MTM claims data; therefore, we were limited by information in the administrative 
data set. Moreover, the data presented are from 2014 and CMS Part D MTM guidance and related 
policies (e.g., Star Measures) have changed since that time. However, these data represent the most 
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recent Part D MTM claims data available to researchers and provide the first, to our knowledge, 
nationally representative estimates of MTM delivery by community pharmacists. Additionally, 2014 CMS 
MTM guidance increased emphasis on CMR receipt by patients residing in long-term care facilities who 
otherwise receive required monthly drug regimen reviews.28 Unfortunately, the long term care status of 
beneficiaries was unavailable in the 2014 data. Therefore, future evaluations should examine the extent 
to which these patients are served and what, if any, variation exists across provider types. It is also 
important to note that our analysis only includes MTM enrolled patients who received at least one CMR 
in 2014; patients who received only TMRs are not reported because most MTM claims data are linked to 
CMR claims. Additionally, given that CMS does not have specific coding for “community pharmacist”, it 
is possible that some CMRs were misattributed to their designated MTM provider cohort. Future CMR 
reporting should include more commonly used nomenclature to distinguish community pharmacists and 
other pharmacist provider types (e.g., ambulatory care) to facilitate program evaluation and research. 
Finally, our analyses only provide estimates pertaining to patient characteristics and Part D MTM 
delivery by pharmacist providers and did not evaluate impacts on patient outcomes. Future research 
should examine the effects of Medicare Part D MTM on patient outcomes, discerning beneficiaries that 





Community pharmacists provided approximately one in five CMRs for Part D MTM eligible beneficiaries 
in 2014. Community pharmacists compared with non-community pharmacist providers completed CMRs 
more quickly, produced more MTP recommendations, but resolved fewer MTPs. There is a need for 
continued focus on the unique opportunities and challenges associated with community pharmacist 
MTM delivery. Future research should explore geographic/racial-ethnic disparities in beneficiaries 
served and strategies to increase negligible MTP resolution by community pharmacists.  
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 Table 1.  
Table 1. CMR Provider Types Among 2014 Sample (N=119,181) 
Provider Type n (%) 
Community Pharmacists 26,337 (22.1%) 
     Local Pharmacist    7,734 (29.4%) 
     MTM Vendor Local Pharmacist    18,603 (70.6%) 
Plan Pharmacists 35,741 (30.0%) 
   Plan Sponsor Pharmacist   25,531 (71.4%) 
   Plan Benefit Manager Pharmacist   10,210 (28.6%) 
MTM Vendor In-house Pharmacist 42,225 (35.4%) 
   MTM Vendor In-House Pharmacist   42,225 (100.0%) 
Other Pharmacists   7,624 (6.4%) 
  LTC Consultant Pharmacist        585 (7.7%) 
  Hospital Pharmacist            0 (0.0%) 
  Pharmacist, Other     7,039 (92.3%) 
Other Providers  7,254 (6.1%) 
  Physician       412 (5.7%) 
  Registered Nurse    1,163 (16.0%) 
  Licensed Practical Nurse       332 (4.6%) 
  Nurse Practitioner    4,971 (68.5%) 
  Physician’s Assistant            0 (0.0%) 
  Other       376 (5.2%) 
 
CMR = comprehensive medication review; LTC = long-term care; MTM = Medication Therapy 
Management. 
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 ble 2. Comparison of Predisposing, Enabling, and Need Characteristics of Medicare Beneficiaries Receiving a CMR by Communi  





CMR Provided By: 
 Community RPh  
n (%) 
Plan RPh  
n (%) p-value† 
MTM Vendor In-
House RPh    n 
(%) p-valu  
tal Beneficiaries by Provider Status  26,337 (25.3%) 35,741 (34.3%)   42,225 (40.5%)   
edisposing Variables           
Mean Age (SD) 75 (6.8) 75 (6.8) 0.04 75 (6.9) <0.001 
Male Gender 9795 (37.2%) 13,551 (37.9%) 0.07 15,887 (37.6%) 0.254 
Race     <0.001   <0.001 
White 18,767 (71.3%) 24,922 (69.7%)  32,322 (76.5%)  
Black 3012 (11.4%) 4727 (13.2%)   5296 (12.5%)   
Asian 512 (1.9%) 1041 (2.9%)   774 (1.8%)   
Hispanic 3743 (14.2%) 4532 (12.7%)   3227 (7.6%)   
North American Native 42 (0.2%) 90 (0.3%)   138 (0.3%)   
Other/Unknown 261 (1.0%) 429 (1.2%)   468 (1.1%)   
abling Variables           
Urban Residence 21,441 (81.4%) 31,665 (88.6%) <0.001 34,335 (81.3%) 0.754 
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 Geographic Region     <0.001   <0.001 
Northeast 2217 (8.4%) 4895 (13.7%)  10,759 (25.5%)  
South 15,183 (57.6%) 11,611 (32.5%)   14,559 (34.5%)   
Midwest 5423 (20.6%) 5943 (16.6%)   9997 (23.7%)   
West 2520 (9.6%) 12,338 (34.5%)   6792 (16.1%)   
Other 994 (3.8%) 954 (2.7%)   118 (0.3%)   
ncome Enrollment Status     <0.001   <0.001 
Dual Medicaid Enrollment 4684 (17.8%) 4711 (13.2%)  7953 (18.8%)  
Qualified Medicare Beneficiary 1307 (5.0%) 993 (2.8%)   1482 (3.5%)   
Specified Low-Income Medicare Beneficiary 1282 (4.9%) 963 (2.7%)   1183 (2.8%)   
No Low Income Subsidy Coverage 19,064 (72.4%) 29,074 (81.3%)   31,607 (74.9%)   
Copayment Status Indicator     <0.001   <0.001 
Catastrophic Coverage During Year 5779 (21.9%) 5899 (16.5%)  10,417 (24.7%)  
Coverage Gap Exposure During Year 10,589 (40.2%) 14,639 (41.0%)   15,605 (37.0%)   
No Coverage Gap Exposure During Year 9969 (37.9%) 15,203 (42.5%)   16,203 (38.4%)   
ed Variables           
Cognitively Impaired 1079 (4.1%) 913 (2.6%) <0.001 503 (1.2%) <0.001 
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 Any Hospitalization 2323 (8.8%) 2175 (6.1%) <0.001 5875 (13.9%) <0.001 
Any ED Visit 2658 (10.1%) 2613 (7.3%) <0.001 6761 (16.0%) <0.001 
Mean Count of Hospitalization (SD) 0.15 (0.6) 0.09 (0.4) <0.001 0.22 (0.7) <0.001 
Mean Count of ED Visits (SD) 0.19 (0.8) 0.12 (0.5) <0.001 0.27 (0.8) <0.001 
Mean Number of Elixhauser Conditions (SD) 0.63 (1.5) 0.43 (1.2) <0.001 1.01 (1.8) <0.001 
Mean Elixhauser Mortality Weight (SD) 1.02 (4.2) 0.68 (3.5) <0.001 1.67 (5.3) <0.001 
ean Therapeutic Drug Classes (SD) 15.20 (5.2) 14.42 (5.2) <0.001 14.87 (5.0) <0.001 
Specific Elixhauser Conditions           
Diabetes 3097 (11.8%) 2900 (8.1%) <0.001 7733 (18.3%) <0.001 
Hypertension 3746 (14.2%) 3875 (10.8%) <0.001 10,101 (23.9%) <0.001 
Congestive Heart Failure 1253 (4.8%) 947 (2.6%) <0.001 2890 (6.8%) <0.001 
Chronic Pulmonary Disease 1492 (5.7%) 1218 (3.4%) <0.001 3297 (7.8%) <0.001 
Depression 587 (2.2%) 404 (1.1%) <0.001 1180 (2.8%) <0.001 
 
CMR = comprehensive medication review; ED = emergency department; MTM = medication therapy 
management; RPh = pharmacist; SD = standard deviation. 
† p-values represent comparisons using t-tests (continuous variables) or chi-square tests (categorical 
variables) between community pharmacist and plan pharmacist cohorts.  
‡ p-values represent comparisons using t-tests (continuous variables) or chi-square tests (categorical 
variables) between community pharmacist and MTM Vendor In-house  pharmacist cohorts. 
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 Table 3. Comparison of MTM Delivery to Beneficiaries Receiving CMRs by Community Pharmacists and Other P   




CMR Provided By: 
 Community RPh  
 n (%) 
Plan RPh  
n (%) p-value† 
MTM  
Ho    
   
Total Beneficiaries by Provider Status  26,337 (25.3%) 35,741 (34.3%)   42,22     
Entry into MTM Program           
Days from Plan Enrollment to MTM Enrollment         
Mean 68.4 (78) 72.9 (83)  79.5 (7   
Median 31 48 <0.001c 33  
25th Percentile 0 0   26   
75th Percentile 100 111   119   
Days from MTM Enrollment to CMR Offer, n (%)         
Mean (SD) 30.5 (33) 17.8 (29)   20.4 (2   
Median 28 9 <0.001§ 16   
25th Percentile 9 0  4  
75th Percentile 38 26  28  
0 174 (0.7%) 11,071 (31.0%)   1,004    
1-30 16,757 (63.6%) 18,394 (51.5%)   32,157    
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 31-60 7915 (30.1%) 5004 (14.0%)   7757 (    
61+ 1491 (5.7%) 1263 (3.5%)   1178 (    
Unknown 0 (0.0%) 9 (0.0%)   129 (0    
Days from CMR Offer to First CMR Received         
Mean 85.5 (86) 101.4 (85)   116.6    
Median 47 76  <0.001§ 94   
25th Percentile 20 32   31   
75th Percentile 140 155   194   
Part D Contract Type, n (%)     0.394    
Managed Care 19,643 (74.6%) 26,543 (74.3%)  19,734    
Prescription Drug Plan 6690 (25.4%) 9188 (25.7%)   22,323    
Employer Sponsored 4 (0.0%) 10 (0.0%)   168 (0    
MTM Services Received           
CMR Delivery Method, n (%)     <0.001    
Face-to-Face 13,010 (49.4%) 380 (1.1%)   9 (0.0%    
Telephone 13,327 (50.6%) 35,361 (98.9%)   42,216    
Telehealth Consultation (Video Conferencing) 0 (0.0%) 0 (0.0%)   0 (0.0%    
CMR Recipient     <0.001    
Beneficiary 23,281 (88.4%) 32,261 (90.3%)  36,246   
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 Beneficiary's Prescriber 53 (0.2%) 7 (0.0%)   14 (0.0    
Caregiver/Other Authorized Individual 3003 (11.4%) 3473 (9.7%)   5965 (    
Mean Number of CMRs Received (SD) 1.01 (0.1) 1.02 (0.1) <0.001 1.03 (0   
Mean Number of Targeted Medication Reviews (SD) 10.29 (8.9) 5.71 (6.7) <0.001 18.36   
MTM Interventions Made           
Mean Number of MTP Recommendations Made to 
Prescribers (SD) 1.80 (3.5) 1.17 (2.5) <0.001 1.64 (2   
Mean Number of MTP Resolutions With Prescribers 
(SD) 0.22 (0.7) 0.33 (0.9) <0.001 0.35 (0   
 
CMR = comprehensive medication review; MTM = Medication Therapy Management; MTP = medication 
therapy problem; RPh = pharmacist; SD = standard deviation. 
† P-values represent comparisons using t-tests (continuous variables) or chi-square tests (categorical 
variables) between community pharmacist and plan pharmacist cohorts.  
‡ P-values represent comparisons using t-tests (continuous variables) or chi-square tests (categorical 
variables) between community pharmacist and MTM Vendor In-house pharmacist cohorts. 
§ P-values represent comparisons using Wilcoxon rank sum tests between community pharmacist and 
plan pharmacist cohorts.  
¶ P-values represent comparisons using Wilcoxon rank sum tests between community pharmacist and 
MTM Vendor In-house pharmacist cohorts. 
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 Figure .  Flow diagram of MTM eligible Medicare beneficiaries receiving CMRs in 2014. CMR = 
comprehensive medication review; ESRD = end-stage renal disease; MTM = medication therapy 
management. † An individual aged 65 or over, who is enrolled in the Medicare program. 
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Figure 1.  Flow Diagram of MTM eligible Medicare Beneficiaries receiving CMRs in 2014
 
Abbreviations: MTM, Medication Therapy Management; CMR, comprehensive medication review; ESRD, end stage renal disease 
a An individual aged 65 or over, who is enrolled in the Medicare program. 
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Table 1. CMR Provider Types Among 2014 Sample (N=119,181) 
Provider Type n (%) 
Community Pharmacists 26,337 (22.1%) 
     Local Pharmacist    7,734 (29.4%) 
     MTM Vendor Local Pharmacist    18,603 (70.6%) 
Plan Pharmacists 35,741 (30.0%) 
   Plan Sponsor Pharmacist   25,531 (71.4%) 
   Plan Benefit Manager Pharmacist   10,210 (28.6%) 
MTM Vendor In-house Pharmacist 42,225 (35.4%) 
   MTM Vendor In-House Pharmacist   42,225 (100.0%) 
Other Pharmacists   7,624 (6.4%) 
  LTC Consultant Pharmacist        585 (7.7%) 
  Hospital Pharmacist            0 (0.0%) 
  Pharmacist, Other     7,039 (92.3%) 
Other Providers  7,254 (6.1%) 
  Physician       412 (5.7%) 
  Registered Nurse    1,163 (16.0%) 
  Licensed Practical Nurse       332 (4.6%) 
  Nurse Practitioner    4,971 (68.5%) 
  Physician’s Assistant            0 (0.0%) 
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  Other       376 (5.2%) 
 
CMR = comprehensive medication review; LTC = long-term care; MTM = Medication Therapy Management. 
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 Table 2. Comparison of Predisposing, Enabling, and Need Characteristics of Medicare Beneficiaries Receiving a CMR by Community 





CMR Provided By: 
 Community RPh  
n (%) 
Plan RPh  
n (%) p-value† 
MTM Vendor 
In-House RPh    
n (%) p-value‡ 
Total Beneficiaries by Provider Status  26,337 (25.3%) 35,741 (34.3%)   42,225 (40.5%)   
Predisposing Variables           
Mean Age (SD) 75 (6.8) 75 (6.8) 0.04 75 (6.9) <0.001 
Male Gender 9795 (37.2%) 13,551 (37.9%) 0.07 15,887 (37.6%) 0.254 
Race     <0.001   <0.001 
White 18,767 (71.3%) 24,922 (69.7%)  32,322 (76.5%)  
Black 3012 (11.4%) 4727 (13.2%)   5296 (12.5%)   
Asian 512 (1.9%) 1041 (2.9%)   774 (1.8%)   
Hispanic 3743 (14.2%) 4532 (12.7%)   3227 (7.6%)   
North American Native 42 (0.2%) 90 (0.3%)   138 (0.3%)   
Other/Unknown 261 (1.0%) 429 (1.2%)   468 (1.1%)   
Enabling Variables           
Urban Residence 21,441 (81.4%) 31,665 (88.6%) <0.001 34,335 (81.3%) 0.754 
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Geographic Region     <0.001   <0.001 
Northeast 2217 (8.4%) 4895 (13.7%)  10,759 (25.5%)  
South 15,183 (57.6%) 11,611 (32.5%)   14,559 (34.5%)   
Midwest 5423 (20.6%) 5943 (16.6%)   9997 (23.7%)   
West 2520 (9.6%) 12,338 (34.5%)   6792 (16.1%)   
Other 994 (3.8%) 954 (2.7%)   118 (0.3%)   
Income Enrollment Status     <0.001   <0.001 
Dual Medicaid Enrollment 4684 (17.8%) 4711 (13.2%)  7953 (18.8%)  
Qualified Medicare 
Beneficiary 1307 (5.0%) 993 (2.8%)   1482 (3.5%)   
Specified Low-Income 
Medicare Beneficiary 1282 (4.9%) 963 (2.7%)   1183 (2.8%)   
No Low Income Subsidy Coverage 19,064 (72.4%) 29,074 (81.3%)   31,607 (74.9%)   
Copayment Status Indicator     <0.001   <0.001 
Catastrophic Coverage During 
Year 5779 (21.9%) 5899 (16.5%)  10,417 (24.7%)  
Coverage Gap Exposure 
During Year 10,589 (40.2%) 14,639 (41.0%)   15,605 (37.0%)   
No Coverage Gap Exposure 
During Year 9969 (37.9%) 15,203 (42.5%)   16,203 (38.4%)   
Need Variables           
Cognitively Impaired 1079 (4.1%) 913 (2.6%) <0.001 503 (1.2%) <0.001 
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Any Hospitalization 2323 (8.8%) 2175 (6.1%) <0.001 5875 (13.9%) <0.001 
Any ED Visit 2658 (10.1%) 2613 (7.3%) <0.001 6761 (16.0%) <0.001 
Mean Count of Hospitalization (SD) 0.15 (0.6) 0.09 (0.4) <0.001 0.22 (0.7) <0.001 
Mean Count of ED Visits (SD) 0.19 (0.8) 0.12 (0.5) <0.001 0.27 (0.8) <0.001 
Mean Number of Elixhauser 
Conditions (SD) 0.63 (1.5) 0.43 (1.2) <0.001 1.01 (1.8) <0.001 
Mean Elixhauser Mortality 
Weight (SD) 1.02 (4.2) 0.68 (3.5) <0.001 1.67 (5.3) <0.001 
Mean Therapeutic Drug Classes (SD) 15.20 (5.2) 14.42 (5.2) <0.001 14.87 (5.0) <0.001 
Specific Elixhauser Conditions           
Diabetes 3097 (11.8%) 2900 (8.1%) <0.001 7733 (18.3%) <0.001 
Hypertension 3746 (14.2%) 3875 (10.8%) <0.001 10,101 (23.9%) <0.001 
Congestive Heart Failure 1253 (4.8%) 947 (2.6%) <0.001 2890 (6.8%) <0.001 
Chronic Pulmonary Disease 1492 (5.7%) 1218 (3.4%) <0.001 3297 (7.8%) <0.001 
Depression 587 (2.2%) 404 (1.1%) <0.001 1180 (2.8%) <0.001 
 
CMR = comprehensive medication review; ED = emergency department; MTM = medication therapy management; RPh = pharmacist; SD = 
standard deviation. 
† p-values represent comparisons using t-tests (continuous variables) or chi-square tests (categorical variables) between community pharmacist 
and plan pharmacist cohorts.  
‡ p-values represent comparisons using t-tests (continuous variables) or chi-square tests (categorical variables) between community pharmacist 
and MTM Vendor In-house  pharmacist cohorts. 
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Table 3. Comparison of MTM Delivery to Beneficiaries Receiving CMRs by Community Pharmacists and Other Pharmacist Provider 




CMR Provided By: 
 Community RPh  
 n (%) 
Plan RPh  
n (%) p-value† 
MTM Vendor In-
House RPh  
n (%) p-value‡ 
Total Beneficiaries by Provider Status  26,337 (25.3%) 35,741 (34.3%)   42,225 (40.5%)   
Entry into MTM Program           
Days from Plan Enrollment to MTM Enrollment         
Mean 68.4 (78) 72.9 (83)  79.5 (78)  
Median 31 48 <0.001c 33 <0.001d 
25th Percentile 0 0   26   
75th Percentile 100 111   119   
Days from MTM Enrollment to CMR Offer, n (%)         
Mean (SD) 30.5 (33) 17.8 (29)   20.4 (20)  
Median 28 9 <0.001§ 16  <0.001¶ 
25th Percentile 9 0  4  
75th Percentile 38 26  28  
0 174 (0.7%) 11,071 (31.0%)   1,004 (2.4%)   
1-30 16,757 (63.6%) 18,394 (51.5%)   32,157 (76.2%)   
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31-60 7915 (30.1%) 5004 (14.0%)   7757 (18.4%)   
61+ 1491 (5.7%) 1263 (3.5%)   1178 (2.8%)   
Unknown 0 (0.0%) 9 (0.0%)   129 (0.3%)   
Days from CMR Offer to First CMR Received         
Mean 85.5 (86) 101.4 (85)   116.6 (93)   
Median 47 76  <0.001§ 94  <0.001¶ 
25th Percentile 20 32   31   
75th Percentile 140 155   194   
Part D Contract Type, n (%)     0.394   <0.001 
Managed Care 19,643 (74.6%) 26,543 (74.3%)  19,734 (46.7%)   
Prescription Drug Plan 6690 (25.4%) 9188 (25.7%)   22,323 (52.9%)   
Employer Sponsored 4 (0.0%) 10 (0.0%)   168 (0.4%)   
MTM Services Received           
CMR Delivery Method, n (%)     <0.001   <0.001 
Face-to-Face 13,010 (49.4%) 380 (1.1%)   9 (0.0%)   
Telephone 13,327 (50.6%) 35,361 (98.9%)   42,216 (100.0%)   
Telehealth Consultation (Video Conferencing) 0 (0.0%) 0 (0.0%)   0 (0.0%)   
CMR Recipient     <0.001   <0.001 
Beneficiary 23,281 (88.4%) 32,261 (90.3%)  36,246 (85.8%)  
Beneficiary's Prescriber 53 (0.2%) 7 (0.0%)   14 (0.0%)   
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Caregiver/Other Authorized Individual 3003 (11.4%) 3473 (9.7%)   5965 (14.1%)   
Mean Number of CMRs Received (SD) 1.01 (0.1) 1.02 (0.1) <0.001 1.03 (0.2) <0.001 
Mean Number of Targeted Medication Reviews (SD) 10.29 (8.9) 5.71 (6.7) <0.001 18.36 (18) <0.001 
MTM Interventions Made           
Mean Number of MTP Recommendations Made to 
Prescribers (SD) 1.80 (3.5) 1.17 (2.5) <0.001 1.64 (2.8) <0.001 
Mean Number of MTP Resolutions With Prescribers 
(SD) 0.22 (0.7) 0.33 (0.9) <0.001 0.35 (0.8) <0.001 
 
CMR = comprehensive medication review; MTM = Medication Therapy Management; MTP = medication therapy problem; RPh = pharmacist; SD 
= standard deviation. 
† P-values represent comparisons using t-tests (continuous variables) or chi-square tests (categorical variables) between community pharmacist 
and plan pharmacist cohorts.  
‡ P-values represent comparisons using t-tests (continuous variables) or chi-square tests (categorical variables) between community pharmacist 
and MTM Vendor In-house pharmacist cohorts. 
§ P-values represent comparisons using Wilcoxon rank sum tests between community pharmacist and plan pharmacist cohorts.  
¶ P-values represent comparisons using Wilcoxon rank sum tests between community pharmacist and MTM Vendor In-house pharmacist 
cohorts. 
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